Health issues
Thoracic Oncology Clinic
Clinic Mission: Management of Thoracic Cancers The Thoracic Oncology Clinic at H.U.B specializes in the multidisciplinary management of patients with lung, pleural, and mediastinal cancers, including:Bronchopulmonary cancers (non-small cell and small cell)Pleural tumors (mesotheliomas and others)Mediastinal tumors (thymomas and others)Pleuro-pulmonary metastasesDiagnostic management is provided through an advanced pulmonary endoscopy unit (bronchoscopic fiberoscopy, GPS navigation, endobronchial ultrasound [EBUS], cryobiopsies, etc.) and close collaboration with a highly skilled team of pathologists and the molecular biology laboratory.The weekly multidisciplinary thoracic oncology meeting (CUB Erasme Hospital and Jules Bordet Institute) brings together top specialists in radiology, nuclear medicine, pneumology, thoracic oncology, thoracic surgery, radiotherapy, pathology, ISO, and other fields. This collaboration is the foundation for evidence-based therapeutic decisions aligned with the latest scientific research and best practice guidelines.Surgical management is provided by the Thoracic Surgery Department, in line with our institution’s long-standing integrated medical-surgical model.Radiotherapy management is provided by the Institut Jules Bordet team.Collaboration with the Gamma Knife Center of the Neurosurgery Department at Erasme Hospital and the Radiotherapy Department at Institut Jules Bordet ensures optimal management of brain metastases. Learn more about lung cancer care at the Jules Bordet Institute Academic Mission Training of medical residents in Pneumology and Internal MedicineTraining in Thoracic OncologySupervisor: CUB Erasme Hospital – J. Bordet Institute (ULB): Dr Mekinda Ngono Zita LéaOthers Research Mission Les activités de recherche clinique et fondamentale sont réalisées en collaboration avec l’Institut Jules Bordet et la faculté de médecine de l’ULB.Depuis la Création de l’Hôpital Universitaire de Bruxelles (HUB) en 2021, la prise en charge des pathologies oncologiques thoraciques se fait dans le cadre d’un projet de soins inter-inhospitalier CUB Hôpital Erasme et l’Institut Jules Bordet. Clinical and fundamental research activities are conducted in collaboration with the Jules Bordet Institute and the ULB Faculty of Medicine.Since the creation of the Brussels University Hospital (HUB) in 2021, the management of thoracic oncological diseases has been organized within an inter-hospital care project between CUB Erasme Hospital and the Jules Bordet Institute. Multidisciplinary Thoracic Oncology Team Dr Mekinda Ngono Zita: Pulmonologist, Thoracic OncologistProf. Thierry Berghmans: Medical OncologistProf. Dimitri Leduc: PulmonologistProf. Benjamin Bondue: PulmonologistDr Blandine Jelli: Pulmonologist, Thoracic OncologistDr Olivier Taton: Pulmonologist, Thoracic OncologistProf. Mariana Brandao: Medical OncologistDr Anouk Goudsmit: Medical OncologistDr Alice Carrette: Pulmonologist, Thoracic OncologistDr Bogdan Grigoriu: PulmonologistDr Youri Sokolow: Thoracic SurgeonDr Maria Ruiz: Thoracic SurgeonDr Maarten Vander Kuylen: Thoracic SurgeonDr Elena Prisciandaro: Thoracic SurgeonProf. Pia Di Campli: Thoracic SurgeonProf. Myriam Remmelink: AnatomopathologistProf. Luigi Moretti: RadiotherapistProf. Caroline Keyzer: Radiologist
Thoracic Oncology Clinic
Health issues
Thrombotic Thrombocytopenic Purpura (TTP)
What is Thrombotic Thrombocytopenic Purpura? TTP or Thrombotic Thrombocytopenic Purpura is a rare disease of the group known as thrombotic  microangiopathies. These are diseases  in which the platelets or thrombocytes (involved in coagulation) clog together in an abnormal manner leading to the formation of blood clots.  This phenomenon causes three problems:A reduction in the number of available platelets = Thrombocytopenia.The red blood cells collide with these clots and break up leading to a reduction in number = Anaemia.The clots can block the blood vessels and reduce the oxygenation of tissues with possible serious consequences for the heart, brain, kidneys, etc.  A number of causes can be responsible for the occurrence of these thrombotic microangiopathies. The TTP is caused by the deficiency of a protein known as   "Adamts 13". This deficiency is most frequently due to the presence of an antibody (= immune TTP) or otherwise it may be a genetic anomaly (congenital TTP).   Treatment TTP must be treated as a vital emergency. Without treatment the mortality rate is 90%. A rapid diagnosis is essential followed by optimal treatment at an expert centre.  Initial treatment of immune TTP consists of two action plans:1.Acute treatmentIncreasing the level of Adamts 13 proteins by means of plasma exchanges: The plasma (the liquid component of the blood that contains cells) is replaced with healthy plasma that serves to increase Adamts 13 levels and remove antibodies.    Since 2019 an innovative medicine specific to TTP has made it possible to prevent the platelets from attaching themselves to each other, thereby resolving the three problems indicated above. This has permitted a clear improvement in the treatment of acute stage patients. Our centre always has this medicine on hand for rapid administration.    2.Fundamental treatmentStopping the production of antibodies that act against Adamts 13. First line treatment consists of the administration of corticoids and a monoclonal antibody that targets the cells that produce the antibodies  Treatment of congenital TTP is based on the administration of plasma. The administration of  synthetic Adamts 13 is not yet reimbursed but is accessible.  All persons suffering from TTP require lifelong monitoring by a haematologist specialising in this type of pathology.    Our specialists Advice TTP can present various and variable symptoms as it can affect a number of organs. The primary clinical manifestation is abnormal bleeding, major hematomas or petechiae (multiple small red/violet marks on the skin).  More severe symptoms can be the signs of a heart attack or stroke.  A blood test showing anaemia and a thrombocytopenia can quickly suggest the diagnosis .Useful links:   Thrombotic Microangiopathies - MaRIH – Rare Immuno-Haematological Diseases Health Network National Reference Centre Microangiopathies TTP Community - Home (Dutch language site)  Make an appointment Focus Our hematology team has gained extensive experience in managing this condition and regularly receives requests for the care of patients from external centers.We regularly collaborate with expert centers from various European countries (France, United Kingdom, Italy).We participate in multidisciplinary consultation meetings with French expert centers. Discover our Hematology Department
Thrombotic Thrombocytopenic Purpura (TTP)
Services
Transplantation
Our role When an organ is no longer functioning (well), a donor can donate their organ. The healthy organ is transplanted to the patient, offering him or her the chance of a return to a normal life.     Image “Organ donation is a part of a system of Belgian and supranational solidarity. We identify the donors and register them with Eurotransplant which then allocates the organs to persons on the waiting list with priority for the most seriously ill. We also manage those on the waiting list and the organs we receive for our patients.”      Professor Thierry Gustot, Director of the H.U.B. Transplant Department. Our specialities Organ transplantation at the H.U.B. is organised transversally per organ and always involving two specialist departments. The Medical Department cares for persons with “organ insufficiencies” while they await a transplant and subsequently provides post-transplant monitoring, most notably managing the anti-rejection treatment and risk of infection. The Surgery Department is responsible for the actual organ removal and transplantation.  Responsibility for heart transplants lies with the Cardiac Insufficiency Clinic (cardiology) and thoracic surgery.Responsibility for lung transplants lies with pneumology for the medical aspects and with thoracic surgery. Responsibility for liver transplants  lies with gastroenterology for the medical aspects and with the Liver Transplant Clinic (digestive surgery).Responsibility for  kidney transplants lies with nephrology for the medical aspects and with the Kidney Transplant Functional Unit (digestive surgery).Overseeing these 4 transplant units is the Transplant Coordination Cell. This team of specialised nurses manages interaction between the donor centres and Eurotransplant as well as the waiting lists and interactions with the specialist doctors in charge of patients waiting for an organ. In the event of compatibility and agreement, the Cell organises the logistics of the transplant: communication with  the patient, secure transport of the organ, mobilisation of the surgery team, reserving of a room in the operating area, etc.    Our Team Image Our medical specialists Focus The H.U.B. Transplant Department has expertise in what liver transplants can contribute in the case of multivisceral insufficiency (kidney, circulation, brain, etc.). The director of the department is also Principal Investigator for a major global study on the subject (CHANCE).     Research The H.U.B. Transplant Department works with the Institute of Medical Immunology on research projects relating to transplant immunology (rejection, organ tolerance, ischaemia-reperfusion, etc.) The department also works on terminal phase liver insufficiency, in partnership with the Experimental Gastroenterology Department.   Teaching The H.U.B. Transplant Department organises the Sympadot, an annual symposium dedicated to the latest progress in organ donation and transplantation. This symposium is for all local coordinators of organ donations within the H.U.B.-ULB network.    Publications Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment : a prospective controlled study. Autors : Louvet A, Labreuche J, Moreno C, Vanlemmens C, Moirand R, et al. Lancet Gastroenterol HepatolJournal : 2022 ;7(5) :416-425. PMID 35202597 A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation. Journal : Am J Transplant 2022 ;22(1) :222-229. PMID 34587371. Long-term outcome after venoarterial extracorporeal mebrane oxygenation as bridge to left ventricular assist device preceding heart transplantation. Autors : Coeckelenbergh S, Valente F, Mortier J, et al.Journal : J Cardiothorac Vasdc Anesth 2022 ;36(6) :1694-1702. PMID 34330577. 5-year outcomes of the prospective and randomized CISTCERT study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients. Journal : Transpl Int 2021 ;34(2) :313-326. PMID : 33277746.
Transplantation - Erasme
Article
Treating Obesity in 2026
On this World Obesity Day, Professor Jean-Charles Preiser, from the Department of Internal Medicine and expert within the team of the Integrated Obesity Centre at H.U.B, explains the new approaches to managing this chronic disease. Prevention, Comprehensive Assessment and a Tailored Approach At the Integrated Obesity Centre of H.U.B, Professor Jean-Charles Preiser from the Department of Internal Medicine sees patients with very different profiles. Some come because of high blood pressure, others for poorly controlled diabetes, joint pain, or sleep disorders. And then there are those who simply walk in and say, “Doctor, I have a problem with my weight.”“My role,” he explains, “is first to have a global vision. Obesity does not affect just one organ. It can involve the heart, the liver, the joints, the metabolism, and sleep.”Behind the word “obesity” there is often a silent accumulation of complications: diabetes, hypertension, sleep apnoea, fatty liver disease, certain cancers. Sometimes already present. Sometimes still invisible.An assessment to understand, not to judgeThe first step is not treatment, but assessment. Blood tests to detect sometimes asymptomatic diabetes. Blood pressure measurement. Sleep evaluation. Screening for liver damage, sometimes completely silent.“We systematically investigate potential complications. Not to make the file heavier, but to guide treatment,” emphasises Professor Preiser.Today, management has evolved. The options are numerous: structured dietary support; psychological support (particularly in cases of eating disorders); drug treatments; and even bariatric surgery for the most severe cases.“A few years ago, surgery represented a significant share of referrals. Today, drug treatments occupy an increasing place. About one patient out of two benefits from them. Surgery concerns a minority of cases, around 20%,” says Professor Preiser.New generations of medications, notably incretin analogues (GLP-1, GIP), have changed the therapeutic landscape. They are part of the current arsenal, with significant results in many patients. But they are neither automatic nor universal. Their cost remains high and reimbursement is limited to certain situations, particularly in cases of poorly controlled diabetes.“There is no single treatment. There is a strategy tailored to each patient,” he insists.“It’s all because of your weight”: moving beyond shortcutsMany patients arrive with a sense of exhaustion: after hearing consultation after consultation that all their symptoms are related to their weight.Dr Preiser nuances this: “Yes, obesity increases the risk of many complications. But the probability of developing a disease is not strictly proportional to the degree of obesity.”Some people living with severe obesity for years present few complications. Others, with more moderate obesity, develop early metabolic or cardiovascular problems.Why? Genetic background plays a major role. Family history — heart attack, stroke, liver disease, diabetes — guides the level of risk. The association with other factors, such as alcohol consumption or smoking, also changes the picture.The message is clear: obesity is an important risk factor, but it does not explain everything. Each situation deserves individual analysis.A new definition: looking at fat mass, not only weightSince 2025, the definition of obesity has evolved: it is no longer only total body weight that matters, but the proportion of fat mass.“The objective is not to make patients lose muscle or water. What we aim for is a reduction in fat mass while preserving muscle mass,” Professor Preiser reminds us.This approach is particularly important in geriatrics, where muscle loss can worsen frailty and increase the risk of falls. Hence the importance of sufficient protein intake and adapted physical activity, even during drug treatment.Men and women: different risksComplications are not identical depending on sex. In women, obesity can lead to fertility disorders or polycystic ovary syndrome. After menopause, the risk of breast cancer increases in cases of obesity. Knee pain is also more frequent.In men, there is a greater accumulation of cardiovascular risk factors and a higher frequency of certain digestive cancers and prostate cancer.In both cases, screening remains essential. Treating obesity after cancer, for example, can help reduce the risk of recurrence.Increasingly younger patientsThe most striking evolution in recent years concerns the age of patients.“Obesity is increasing among children and adolescents, often against a background of socio-economic and cultural factors. Sedentary lifestyles, accentuated by the COVID period, have played a role. Many obese young people become obese adults,” laments Professor Preiser.Some consult spontaneously, with a desire to understand and act early.Other situations are emerging: women undergoing medically assisted reproduction, where obesity management and fertility treatment occur in parallel. After childbirth, priority may shift to the newborn, pushing maternal health into the background. “These are human realities that must be integrated into care,” the geriatrician points out.The sensitive issue of relapseObesity is a chronic disease. Like any chronic disease, it can lead to relapse.After surgery, very rapid weight loss can lead to deficiencies or malabsorption problems, and weight regain may occur. With dieting alone, the “yo-yo effect” remains the typical failure when recommendations are not adapted to lifestyle or when an eating disorder is not addressed.Regarding recent medications, long-term data are still limited. Doses are adjusted progressively according to individual response and side effects. Discontinuation must be gradual, accompanied by increased physical activity and sufficient protein intake to preserve muscle mass. Strategies can be combined: drug treatment before or after surgery, reintroduction in case of weight regain.“The key is continuity of follow-up,” insists Professor Preiser.Changing the way we look at obesity and its managementSome patients arrive with a clear idea: “I want surgery” or “I want this new medication.” Sometimes they leave with a different proposal after a full assessment.“Our role is to explain that several options exist and that the choice depends on the overall medical evaluation,” Professor Preiser recalls.Obesity is not just a number on a scale. Nor is it a personal failure. It is a chronic, multifactorial disease, influenced by genetics, environment, lifestyle, and social context.Treating it is not only about losing weight. It is about preventing complications, preserving quality of life, rebuilding self-esteem, overcoming emotional wounds and destructive habits and, in the most severe cases, maintaining autonomy.For those living with obesity — or supporting a loved one affected by obesity — the message may be this: solutions exist. They are multiple, personalised, and evolving. And above all, they are built together with the patient, step by step, throughout their care pathway and life journey.Multidisciplinary team-based careAt H.U.B, care is multidisciplinary: internists, endocrinologists, dietitians, psychologists, gastroenterologists, hepatologists, cardiologists, and sleep specialists. This network organisation prevents patients from facing a complex disease alone. Contact the Obesity Centre Pr. Jean-Charles Preiser Also read: The role of dietetics in the multidisciplinary management of obesityIngrid Hanson, a dietitian accredited by the Federal Public Service for Public Health at the Integrated Obesity Center of H.U.B., explains the delicate issue of nutrition for patients who wish or need to lose weight. Discover the interview.